HRTS Cardiovascular and Metabolic ETF
5 Reasons to Consider
Underpenetrated, large market
Obesity is forecast to affect one in four people globally by 2035, and obesity-related conditions like diabetes and heart disease represent vast markets with significant growth potential.
Source: World Obesity Atlas, March 2023.
Innovation
Research expertise
Barriers to entry
Uncorrelated
Underpenetrated, large market
Obesity is forecast to affect one in four people globally by 2035, and obesity-related conditions like diabetes and heart disease represent vast markets with significant growth potential.
Source: World Obesity Atlas, March 2023.
Innovation
Research expertise
Barriers to entry
Uncorrelated
Fund Overview
Fund Details
As of December 6, 2023- Primary Exchange Nasdaq
- Ticker HRTS
- Cusip 87975E883
- Median Bid/Ask Spread (30 Day) 0.38%
- Fund Inception Date November 20, 2023
- Gross Expense Ratio 0.99%
- Net Expense Ratio 0.75%
- Shares Outstanding 470,000
- Number of Holdings 42
- Investment Adviser Tema Global Limited
- Sub-Investment Adviser NEOS Investments, LLC
- Distributor Foreside Fund Services, LLC
- Portfolio Manager David K. Song, MD, PhD, CFA
Fund Summary
The actively managed Tema Cardiovascular and Metabolic ETF seeks to provide long-term growth of capital by investing in companies leading the fight against diabetes, obesity and cardiovascular diseases. Obesity is on the cusp of a revolution in therapeutics, while heart disease, the most common cause of death, is witnessing a renaissance of therapies driven by genetic insights and tools. The complex combination of scientific, regulatory and financing risks requires investment and scientific expertise to navigate this secular theme.
Source: Our World in Data, November 2023.
Fund Documents
Portfolio Breakdown
Top 10 holdings
As of December 6, 2023- Company% Nav
Country Breakdown
Industry Breakdown
Fund Insights & Media
Prices & Performance
HRTS
3 months
YTD
1 Year
3 Years
5 Years
Since Inception
As of November 30, 2023December 08, 2023
Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.
The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.
HRTS Nav/Market Price
Distributions
HRTS
Month
Ex Date
Record Date
Pay Date
Dividend
Premium/Discount
Days Traded at Nav
Days Traded at Premium
Days Traded at Discount
How to Buy
